FDA Approves Eskata for Raised Seborrheic Keratoses

December 18, 2017


The FDA has approved a topical, high-concentration hydrogen peroxide solution for raised seborrheic keratoses, according to a company press release.
Aclaris Therapeutics announced that the Food and Drug Administration (FDA) has approved Eskata (hydrogen peroxide) topical solution for the treatment of raised seborrheic keratoses. Eskata is a high-concentration hydrogen peroxide-based topical solution intended for application in office by a healthcare provider. The pen-like applicator allows for a direct treatment application.

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • The Beauty Health Company (SKIN) Rebrands to SkinHealth Systems
    • Amazon Launches GLP-1 Weight Loss Program with One Medical
    • Botox Cosmetic’s “The Confidence Collective” to Empower 250 Women Entrepreneurs
    • Medical Spa Show 2027 Call for Presentations Now Open
    • FDA Warning Letter to Texas Medical Spa Signals Increased Compliance Enforcement